Mayo Clinic has one of the leading reference laboratories in the world that performs elemental analysis and metal testing for patients. Paul Jannetto, Ph.D., discusses Mayo’s testing menu and services.
Mayo Clinic physicians, genetic counselors, and allied health staff are in San Diego for the WORLDSymposium, which presents the latest information from basic science, translational research, and clinical trials for lysosomal diseases. If you are at the meeting, visit us at booth #23.
The U.S. Food and Drug Administration recently updated its electronic filing requirements for importing goods, including biological specimens. Full enforcement of the new requirements will begin on Thursday, February 9, at 6 a.m. EST.
Using targeted next-generation sequencing to identify lung tumors that may respond to targeted therapies by assessing somatic mutations simultaneously within EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2 and MET and identifying rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.
The recommendations surrounding newborn screening are constantly in flux. Newly discovered treatments or emerging laboratory technologies are enabling additional recommendations for newborn screening.
In an effort to develop a better and more consistent flow to the Mayo Medical Laboratories Test Catalog, six new fields have been added. The “Specimen Required” section has also been reorganized.
Matt Binnicker, Ph.D., Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic, recently presented on the Clinician Outreach and Communication Activity call, “Updated CDC Zika Laboratory Testing Guidance.”
Designed specifically to meet the practice demands of physicians and other health care providers, our refreshed and updated reports format were made available to MayoLINK users.
In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.